6 semaglutide Cardiovascular risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN trial Semaglutide Impurity 6 | CAS

Lemmer IL, Willemsen N, Hilal N, Bartelt A

Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells

Based on todays evidence: Injections produce the highest overall weight loss Oral options offer unmatched convenience with strong early results Both are effective for people with obesity or type 2 diabetes For many patients, the choice is not just which is stronger? But its which is easier to stay on long-term? Side Effects: What the Study Found The clinical trial results for GLP-1 treatments show that orforglipron has a similar side-effect pattern to other GLP-1 receptor agonists: most issues are gastrointestinal and mild to moderate

Several handling errors can compromise semaglutide safety and effectiveness

Individual results vary considerably